Background: Radiation necrosis is 1 of the most significant complications of brain tumor irradiation. The standard treatment for patients with radiation necrosis consists of corticosteroids to reduce the amount of cerebral edema and, if required, cyst drainage. Case Reports: 2 patients with symptomatic radiation necrosis initially unresponsive to steroid treatment were treated with repeated low-dose bevacizumab at 5 mg/kg body weight. Rapid and lasting symptom relief, as well as neuroradiological improvement was seen in both cases. A dramatic rapid magnetic resonance imaging response with decrease in contrast enhancement was found shortly after administering the first dose of bevacizumab. The improvement of perifocal edema was relatively slower than of the reduction of enhancement. Only a slight reduction in size of the involved area could be expected after the first dose of bevacizumab. Further shrinkage was seen after the second and third doses. The individuals reported have been doing well for more than 45 and 22 months, respectively, after the initiation of bevacizumab treatment. Conclusion: Our data add to the literature supporting of the use of bevacizumab as an effective therapeutic agent for radiation necrosis, particularly in cases unresponsive to steroid treatment.

Journal Section:
Novel Insights from Clinical Practice
Keywords:
Cerebral, Radiation necrosis, Bevacizumab, Long-term relief
1.
Sheline GE, Wara WM, Smith V: Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 1980;6:1215-1228.
[PubMed]
https://doi.org/10.1016/0360-3016(80)90175-3
2.
Fokas E, Wacker U, Gross MW, et al.: Hypofractionated stereotactic reirradiation of recurrent glioblastomas: A beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol 2009;185:235-240.
[PubMed]
https://doi.org/10.1007/s00066-009-1753-x
3.
Marks JE, Wong J: The risk of cerebral radionecrosis in relation to dose, time and fractionation. A follow-up study. Prog Exp Tumor Res 1985;29:210-218.
[PubMed]
4.
Wilson CM, Gaber MW, Sabek OM, et al.: Radiation-induced astrogliosis and blood-brain barrier damage can be abrogated using anti-TNF treatment. Int J Radiat Oncol Biol Phys 2009;74:934-941.
[PubMed]
https://doi.org/10.1016/j.ijrobp.2009.02.035
5.
Giglio P, Gilbert MR: Cerebral radiation necrosis. Neurologist 2003;9:180-188.
[PubMed]
https://doi.org/10.1097/01.nrl.0000080951.78533.c4
6.
Cross NE, Glantz MJ: Neurologic complications of radiation therapy. Neurol Clin 2003;21:249-277.
[PubMed]
https://doi.org/10.1007/978-1-59745-412-4_16
7.
Murovic JA, Chang SD: The pathophysiology of cerebral radiation necrosis and the role of laser interstitial thermal therapy. World Neurosurg 2015;83:23-26.
[PubMed]
https://doi.org/10.1016/j.wneu.2014.03.015
8.
Brandes AA, Tosoni A, Spagnolli F, et al.: Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology. Neuro Oncol 2008;10:361-367.
[PubMed]
https://doi.org/10.1215/15228517-2008-008
9.
Peca C, Pacelli R, Elefante A, et al.: Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: Tumour progression or radionecrosis? Clin Neurol Neurosurg 2009;111:331-334.
[PubMed]
https://doi.org/10.1016/j.clineuro.2008.11.003
10.
Cheung MC, Chan AS, Law SC, et al.: Impact of radionecrosis on cognitive dysfunction in patients after radiotherapy for nasopharyngeal carcinoma. Cancer 2003;97:2019-2026.
[PubMed]
https://doi.org/10.1002/cncr.11295
11.
Gonzalez J, Kumar AJ, Conrad CA, Levin VA: Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007;67:323-326.
[PubMed]
https://doi.org/10.1016/j.ijrobp.2006.10.010
12.
Wick W, Chinot OL, Bendszus M, et al.: Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro Oncol 2016;18:1434-1441.
[PubMed]
https://doi.org/10.1093/neuonc/now091
13.
Brandes AA, Franceschi E, Tosoni A, et al.: MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008;26:2192-2197.
[PubMed]
https://doi.org/10.1200/JCO.2007.14.8163
14.
Torcuator R, Zuniga R, Mohan YS, et al.: Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 2009;94:63-68.
[PubMed]
https://doi.org/10.1007/s11060-009-9801-z
15.
Levin VA, Bidaut L, Hou P, et al.: Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011;79:1487-1495.
[PubMed]
https://doi.org/10.1016/j.ijrobp.2009.12.061
16.
Wang Y, Pan L, Sheng X, et al.: Reversal of cerebral radiation necrosis with bevacizumab treatment in 17 Chinese patients. Eur J Med Res 2012;17:25.
[PubMed]
https://doi.org/10.1186/2047-783X-17-25
© 2017 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.